hepg2 liver carcinoma  (ATCC)

Journal: Molecules

Article Title: Metabolomics, Molecular Networking and Phytochemical Investigation of Psiadia dentata (Cass.) DC., Endemic to Reunion Island: Discovery of Novel Bioactive Molecules

doi: 10.3390/molecules31060973

Figure Lengend Snippet: In vitro cytotoxic activity (HepG2 and HT29 cancer cell lines) of isolated compounds (IC 50 in μg/mL). Active compound: 5–15 µg/mL, moderately active compound: 15–50 µg/mL, inactive compound (IC 50 ≥ 50 μg/mL) [ , ].

Article Snippet: HepG2 human liver hepatocellular carcinoma and HT29 human colorectal adenocarcinoma cells, provided by ATCC HTB-38 were used to assess the toxicity of crude extracts, fractions and pure compounds.

Techniques: In Vitro, Activity Assay, Isolation

Journal: Scientific Reports

Article Title: Integrated safety and microbiota profiling of fulvic acid formulations across in vitro and in vivo models

doi: 10.1038/s41598-026-37331-2

Figure Lengend Snippet: Genotoxic effect observed on LoVo (left) and HepG2 (right) cell lines after 24 h incubation with tested preparations containing fulvic acid (MLG-50, MLG-A50) in the range of 1:8192–1:32768. Nucleus damage presented as tail DNA [%] (Lucia Comet Assay™, Laboratory Imaging). PBS was used as a non-treated control (NTC), and 50 µg/mL H 2 O 2 as a treated control. For each independent experiment, 50–100 nucleoids were randomly analyzed per condition. Data are shown as mean ± standard error of the mean (SEM) from four independent experiments ( n = 4). Statistics were performed using one-way analysis of variance (ANOVA) followed by Dunnett’s multiple comparisons test; * indicates statistical significance versus the non-treated control (NTC) ( p < 0.05). Criteria for interpretation of damage levels were as follows: ≤5%—no or minor damage; 5–20%—low damage; 20–40%—moderate damage; 40–75%—high damage; >75%—severe damage.

Article Snippet: The L929 mouse skin fibroblasts (CCL-1, ATCC, USA) and THP1-BlueTM NF-κB reporter cells (InvivoGen, USA) were cultured in RPMI-1640 medium (Gibco, USA), human colorectal adenocarcinoma LoVo cells (CCL-229, ATCC, USA) were cultured in DMEM/F12 medium (Gibco, USA), and human liver carcinoma HepG2 cells (HB-8065, ATCC, USA) were maintained in DMEM (Gibco, USA).

Techniques: Incubation, Lucia Comet Assay, Imaging, Control

Journal: International Journal of Molecular Sciences

Article Title: Graphene-Based Nanosystem for Targeted Delivery of Anti-Sense miRNA-21 on Hepatocellular Carcinoma Cells

doi: 10.3390/ijms27020975

Figure Lengend Snippet: Cell viability of HepG2 cells after treatment with graphene oxide, antisense miRNA-21 and GO–antisense miRNA-21 nanosystems. ( A ) Viability (%) after 24 h exposure to increasing concentrations of GO (5–50 µg/mL), measured by MTT assay, untreated cells were used as control. ( B ) Analysis of cell viability after 24 h following treatment with GO (10 µg/mL), antisense miRNA-21 (5 pmol/mL), and GO–antisense miRNA-21 (10 µg/mL GO + 5 pmol/mL antisense). Data are expressed as percentage relative to untreated control cells. Data are presented as mean ± SD (n = 3). Statistical analysis was performed using one-way ANOVA followed by Tukey’s post hoc test. Asterisks indicate statistical significance: **** p < 0.0001. Horizontal lines above bars indicate the groups being compared. Abbreviation: Electroporation CTR: electroporation control.

Article Snippet: HepG2 human liver carcinoma cells (ATCC ® HB-8065TM) were cultured in DMEM supplemented with 10% FBS and 1% penicillin/streptomycin.

Techniques: MTT Assay, Control, Electroporation

Journal: International Journal of Molecular Sciences

Article Title: Graphene-Based Nanosystem for Targeted Delivery of Anti-Sense miRNA-21 on Hepatocellular Carcinoma Cells

doi: 10.3390/ijms27020975

Figure Lengend Snippet: Evaluation of cellular uptake efficiency of GO, antisense miRNA-21, and GO–antisense miRNA-21 nanosystems in HepG2 cells. ( A ) Flow cytometry analysis of HepG2 cells treated with FITC-labeled GO, antisense miRNA-21, and GO–antisense miRNA-21 for 24 h. The x-axis represents FITC fluorescence intensity, corresponding to the intracellular uptake level of the labeled constructs. Fluorescence intensity was measured to determine the proportion of FITC-positive cells. ( B ) Confocal microscopy imaging of FITC-labeled (green color) constructs in HepG2 cells after 24 h incubation. Cells were counterstained with DAPI (nuclei- blue color) and ActinRed (cytoskeleton-red color). Scale bar: 50 µm. ( C ) Quantitative analysis by flow cytometry showing the percentage of FITC-positive cells after treatment with GO, antisense miRNA-21, and the GO-antisense complex. Data are presented as mean ± SEM.

Article Snippet: HepG2 human liver carcinoma cells (ATCC ® HB-8065TM) were cultured in DMEM supplemented with 10% FBS and 1% penicillin/streptomycin.

Techniques: Flow Cytometry, Labeling, Fluorescence, Construct, Confocal Microscopy, Imaging, Incubation

Journal: International Journal of Molecular Sciences

Article Title: Graphene-Based Nanosystem for Targeted Delivery of Anti-Sense miRNA-21 on Hepatocellular Carcinoma Cells

doi: 10.3390/ijms27020975

Figure Lengend Snippet: Quantitative real-time PCR analysis of miRNA expression and pro-inflammatory and tumor-related gene expression in HepG2 cells. ( A ) Transcriptional levels of miRNA-21 in untreated HepG2 cells and in cells treated with GO (10 µg/mL) and with Antisense miRNA-21 (5 pmol/mL) for 24 h. ( B ) Transcriptional levels of IL-8, MCP-1, ICAM-1, TIMP-2 and NF-κB in HepG2 cells. The cells were untreated and treated with GO (10 µg/mL) and GO-antisense miRNA-21 (GO 10 µg/mL + antisense miRNA-21 5 pmol/mL) for 24 h. After, the cells were collected for total RNA extraction. The transcriptional levels of the considered genes were analyzed by calculating the value of 2 −ΔΔCt . The assay was performed in triplicate ± SD and expressed as a fold change over the housekeeping genes. **** p < 0.0001; *** p < 0.001; ** p < 0.01; * p < 0.05.

Article Snippet: HepG2 human liver carcinoma cells (ATCC ® HB-8065TM) were cultured in DMEM supplemented with 10% FBS and 1% penicillin/streptomycin.

Techniques: Real-time Polymerase Chain Reaction, Expressing, Gene Expression, RNA Extraction